Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KIORA PHARMACEUTICALS INCEYEG · Entity 7940 | Chief Commercial Officer | July 10, 2018 | July 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KIORA PHARMACEUTICALS INC
Report date July 10, 2018 · Filed July 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,250 |
Reported balance
After 2018-07-10 transaction · row 1
1 source rowRow 1 · 2018-07-10 · Grant · Acquired 25,000 · Balance 196,250 F1: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on July 10, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on July 10, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2018 Filed Jul 12, 2018 21:04 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-038194 · tv498483_4.xml · nonDerivative · entry 1 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,250 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on July 10, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:24 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | PurchaseWarrants (right to buy) · Derivative | 156,250 | Not disclosed Strike: $0.32 | Not disclosed |
DisclosureSEC source: 0001144204-18-021207 · tv491364_4.xml · derivative · entry 2 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,250 Underlying: Common Stock · 156,250 shares Expires 2023-04-17 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:24 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | PurchaseCommon Stock | 156,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-021207 · tv491364_4.xml · nonDerivative · entry 1 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,250 F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32. Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 23:53 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001144204-17-060013 · tv479901_4.xml · derivative · entry 1 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-11-17 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on November 1, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| November 17, 2017 Filed Nov 22, 2017 21:15 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantCommon Stock | 15,000 | $1.07 | $16,050.00 |
DisclosureSEC source: 0001144204-17-060667 · tv480167_4.xml · nonDerivative · entry 1 Garanzini Michael · CIK 0001722844 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.088, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.